MACK Merrimack Pharmaceuticals Inc.

-0.32  -3%
Previous Close 9.47
Open 9.47
Price To Book 1.54
Market Cap 122086474
Shares 13,342,784
Volume 1,481,732
Short Ratio 19.64
Av. Daily Volume 112,341

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial enrolling.
HER2 negative metastatic breast cancer
Phase 2 completion of enrollment announced June 19, 2017. Data due 1H 2018.
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
Cancer - HER2-positive locally advanced or metastatic breast cancer
Approved October 22, 2015.
Cancer - second line pancreatic
Phase 2 initiated mid Feb 2015. Data due 2H 2018.
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
Cancer - front line pancreatic
Phase 1 safety data due 2H 2018.
Solid tumors
Poster at ASCO June 2018.
Solid tumors

Latest News

  1. Options Traders Expect Huge Moves in Merrimack Pharmaceuticals (MACK) Stock
  2. Why is Merrimack (MACK) Up 6.3% Since Its Last Earnings Report?
  3. Edited Transcript of MACK earnings conference call or presentation 8-May-18 12:30pm GMT
  4. Research Report Identifies AngioDynamics, Kaiser Aluminum, Mammoth Energy Services, Meridian Bioscience, Merrimack Pharmaceuticals, and Energizer with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  5. Merrimack to Present at the 2018 American Society of Clinical Oncology Annual Meeting
  6. Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1
  7. Merrimack Reports First Quarter 2018 Financial Results
  8. What's in the Cards for Merrimack (MACK) in Q1 Earnings?
  9. Merrimack Announces Timing of First Quarter 2018 Investor Conference Call
  10. Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting
  11. Consolidated Research: 2018 Summary Expectations for Merrimack Pharmaceuticals, Monroe Capital, NL Industries, FCB Financial, Amtech, and Otter Tail — Fundamental Analysis, Key Performance Indications
  12. Wired News – Merrimack Expanded Enrollment in Ongoing Randomized Phase-2 SHERLOC Trial of MM-121 in Non-Small Cell Lung Cancer
  13. Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
  14. Edited Transcript of MACK earnings conference call or presentation 12-Mar-18 12:30pm GMT
  15. Merrimack Pharmaceuticals, Inc. to Host Earnings Call
  16. Merrimack Provides Business Update and Reports 2017 Financial Results
  17. Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer
  18. Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care Conference
  19. Are Earnings Prospects Improving For Loss-Making Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK)?
  20. Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer